Research and Markets: Prostate Cancer Therapeutics - A Global Market Perspective

Growth in prostate cancer therapies can be attributed to the increase in number of prostate cancer incidences in men aged more than 60 years. Given the longevity of an average individual, and the rapidly aging world population, the risk of prostate cancer stands tall. Invasive cancer carries a high risk of spreading to the bone if left untreated, thereby making timely intervention of crucial importance. The market for world prostate cancer therapeutics continues to gain traction as companies explore advancements and improvements in drug delivery techniques translating to greater market opportunity.

Several options exist for treating prostate cancer in its early development stage. Radiation therapy or surgery offer effective cure when the disease is diagnosed in initial stages. External Beam Radiation Therapy entails release of radioactive beams, either exclusively to the prostate gland (radiation only for prostate) or may cover the adjacent pelvic lymph glands besides the prostate gland (full pelvic radiation). In Brachytherapy or crevice insertions, the surgeon keeps tiny seeds or pallets of radioactive substance straight inside the prostate gland.

These and other market data and trends are presented in "Prostate Cancer Therapeutics: A Global Market Perspective" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

Key Topics Covered:

1. Methodology

2. Global Market Overview And Outlook

3. Clinical Trials

4. Product Facts

5. Corporate Developments

6. Major Players

7. Global Market Analytics

8. The United States

10. Rest Of World

Companies Profiled

- Abbott Laboratories (USA)

- AaEURterna Zentaris Inc.

- ALZA Corporation (USA)

- Amgen Inc. (USA)

- AstraZeneca PLC (UK)

- Medimmune, LLC (USA)

- Bristol-Myers Squibb Company (USA)

- Cell Genesys Inc. (USA)

- Dendreon Corporation (USA)

- EUSA Pharma, (USA) Inc. (USA)

- F. Hoffmann-La Roche Ltd. (Switzerland)

- Genentech Inc. (USA)

- GlaxoSmithKline Plc (UK)

- Immunomedics, Inc. (USA)

- Novartis AG (Switzerland)

- OSI Pharmaceuticals, Inc. (USA)

- Paladin Labs Inc. (Canada)

- Pfizer Inc. (USA)

- Progenics Pharmaceuticals, Inc. (USA)

- Sanofi-Aventis SA (France)

- Spectrum Pharmaceuticals, Inc. (USA)

- Takeda Pharmaceutical Company Limited (Japan)

For more information visit http://www.researchandmarkets.com/research/aee05a/prostate_cancer_th

CONTACT: Laura Wood, Senior Manager, Research and Markets
Fax: +1 646 607 1907 (from USA)
Fax: +353 1 481 1716 (rest of the world)
e-mail: press@researchandmarkets.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (CTHP) CTHP. (CTHP) has Short Term PowerRatings at TradingMarkets. Details on (CTHP) Short Term PowerRatings is available at This Link.